You are here: Home » News-CM » Companies » News
Business Standard

Zydus Cadila receives USFDA approval for Cisatracurium Besylate Injection

Capital Market 

Zydus Cadila has received final approval from the USFDA to market Cisatracurium Besylate Injection USP (US RLD: Nimbex ) in the strength of 20 mg (base)/10 mL (2 mg/mL) Multiple-Dose Vial.

Cisatracurium Besylate is a nondepolarizing skeletal neuromuscular blocker for intravenous administration.

It is an adjunct to general anaesthesia to facilitate tracheal intubation in adults and in paediatric patients 1 month to 12 years of age and to provide skeletal muscle relaxation in adults during surgical procedures or during mechanical ventilation in the ICU. The drug will be manufactured at Liva plant of Cadila Healthcare.

The group now has 297 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, September 02 2020. 16:05 IST